OncoMatch/Clinical Trials/NCT04863950
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
Is NCT04863950 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Lomustine and Imipramine Hydrochloride for glioblastoma.
Treatment: Lomustine · Imipramine Hydrochloride — This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiation therapy — standard combined modality
progression following standard combined modality treatment with radiation and temozolomide chemotherapy
Must have received: chemotherapy (temozolomide) — standard combined modality
progression following standard combined modality treatment with radiation and temozolomide chemotherapy
Cannot have received: non-standard radiation therapy
Exception: stereotactic radiosurgery (SRS) is allowed
Non-standard radiation therapy such as brachytherapy, systemic radioisotope therapy (RIT), or intra-operative radiotherapy (IORT). Note: stereotactic radiosurgery (SRS) is allowed
Cannot have received: systemic therapy (non-bevacizumab systemic therapy, investigational agents, small-molecule kinase inhibitors, non-cytotoxic hormonal therapy (e.g., tamoxifen))
Non-bevacizumab systemic therapy (including investigational agents and small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy (eg, tamoxifen) within 7 days or 5 half-lives, whichever is shorter, prior to first dose of study drug
Cannot have received: biologic agents (antibodies, immune modulators, vaccines, cytokines)
Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to first dose of study drug
Cannot have received: nitrosoureas
Nitrosoureas or mitomycin C within 42 days, or metronomic/protracted low-dose chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 days, prior to first dose of study drug
Cannot have received: mitomycin C (mitomycin C)
Nitrosoureas or mitomycin C within 42 days, or metronomic/protracted low-dose chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 days, prior to first dose of study drug
Cannot have received: chemotherapy (metronomic/protracted low-dose chemotherapy)
metronomic/protracted low-dose chemotherapy within 14 days
Cannot have received: cytotoxic chemotherapy
other cytotoxic chemotherapy within 28 days
Cannot have received: carmustine wafer (carmustine wafer)
Prior treatment with carmustine wafers
Lab requirements
Blood counts
ANC ≥1500 cells/uL; Platelet count ≥100,000/uL; Hemoglobin ≥9.0 g/dL
Kidney function
Serum creatinine ≤ULN
Liver function
Bilirubin ≤ 1.5 times upper limit of normal; AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal (ULN)
acceptable liver function: Bilirubin ≤ 1.5x ULN; AST and ALT ≤ 3.0x ULN; acceptable renal function: Serum creatinine ≤ULN; acceptable hematologic status: ANC ≥1500 cells/uL; Platelet count ≥100,000/uL; Hemoglobin ≥9.0 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mays Cancer Center, UT Health San Antonio · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify